このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Kyung Nam PharmLtd マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Oh Hwan

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected

Aug 19

Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price

May 21

Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?

Mar 21

CEO（最高経営責任者

Oh Hwan

no data

在職期間

Mr. Oh Chang Hwan has been the Chief Executive Officer of Kyung Nam Pharm Co.,Ltd. since January 22, 2013.

Kyung Nam PharmLtd マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected

Less than half of directors are independent

Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion.

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion

Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Less than half of directors are independent

Less than half of directors are independent

Full year 2020 earnings released: ₩318 loss per share (vs ₩293 loss in FY 2019)

New 90-day low: ₩7,730

New 90-day high - ₩11,350

New 90-day low - ₩7,150

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950), Virtualtek Corp (KOSDAQ:A036620) and Ventage Partners Co., Ltd. agreed to acquire 9.32% stake in Livefinancial Co.,Ltd. (KOSDAQ:A036170) for KRW 5.8 billion.

CEO（最高経営責任者

在職期間

Kyung Nam PharmLtd マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:053950) Stock Rockets 37% As Investors Are Less Pessimistic Than Expected

Less than half of directors are independent

Subdued Growth No Barrier To Kyung Nam Pharm Co.,Ltd.'s (KOSDAQ:053950) Price

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion.

RFTech Co., Ltd. Bionanotechnology Co., Ltd. and Lee Gyeong Sook agreed to acquire a 32.69% stake in Enterpartners Co., LTD (KOSDAQ:A058450) from Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950) for KRW 23 billion

Does Kyung Nam PharmLtd (KOSDAQ:053950) Have A Healthy Balance Sheet?

New minor risk - Share price stability

Less than half of directors are independent

Less than half of directors are independent

Full year 2020 earnings released: ₩318 loss per share (vs ₩293 loss in FY 2019)

New 90-day low: ₩7,730

New 90-day high - ₩11,350

New 90-day low - ₩7,150

Kyung Nam Pharm Co.,Ltd. (KOSDAQ:A053950), Virtualtek Corp (KOSDAQ:A036620) and Ventage Partners Co., Ltd. agreed to acquire 9.32% stake in Livefinancial Co.,Ltd. (KOSDAQ:A036170) for KRW 5.8 billion.

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04